A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/20/2006	EP1732925A1 Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors
12/20/2006	EP1732923A2 Muscarinic acetylcholine receptor antagonists
12/20/2006	EP1732922A1 Methods for minimizing thioamide impurities
12/20/2006	EP1732921A1 Thioamide derivatives as progesterone receptor modulators
12/20/2006	EP1732920A2 Thiophene derivatives as chk 1 inhibitors
12/20/2006	EP1732919A1 Substituted thiophene derivatives as anti-cancer agents
12/20/2006	EP1732918A1 Novel pyrrolidine-3,4-dicarboxamide derivatives
12/20/2006	EP1732917A1 Selected cgrp antagonists, methods for the production thereof and their use as medicaments
12/20/2006	EP1732913A1 Chromone complexes
12/20/2006	EP1732909A1 Water soluble esters of ¬n-(4-amino-2-butynyl)\| with anticancer activity
12/20/2006	EP1732907A1 Peptide deformylase inhibitors
12/20/2006	EP1732906A1 2-aminothiazole compounds useful as aspartyl protease inhibitors
12/20/2006	EP1732905A1 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
12/20/2006	EP1732903A1 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd
12/20/2006	EP1732902A2 Nucleoside derivatives and therapeutic use thereof
12/20/2006	EP1732901A1 Antiviral 4-aminocarbonylamino-substituted imidazole compound
12/20/2006	EP1732900A2 Acrylonitrile derivatives for inflammation and immune-related uses
12/20/2006	EP1732898A1 Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors
12/20/2006	EP1732897A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
12/20/2006	EP1732896A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
12/20/2006	EP1732893A2 Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
12/20/2006	EP1732892A1 Tetrahydrocarbazoles and derivatives
12/20/2006	EP1732891A1 Resistance-repellent retroviral protease inhibitors
12/20/2006	EP1732890A1 Crystalline polymorph of a bazedoxifene acetate
12/20/2006	EP1732889A1 Crystalline polymorph of bazedoxifene acetate
12/20/2006	EP1732888A1 Bazedoxifene ascorbate as selective estrogen receptor modulator
12/20/2006	EP1732887A1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
12/20/2006	EP1732884A1 Sulphonamide derivatives
12/20/2006	EP1732883A1 Novel urea derivatives and their medical use
12/20/2006	EP1732878A2 Method for the synthesis of quaternary ammonium compounds and compositions thereof
12/20/2006	EP1732611A1 Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd
12/20/2006	EP1732610A2 Targeted serotonin reuptake inhibitors
12/20/2006	EP1732605A2 Multi-vitamin and mineral nutritional supplements
12/20/2006	EP1732604A2 Methods of treating hiv infection
12/20/2006	EP1732590A2 New pharmaceutical composition based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins
12/20/2006	EP1732583A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
12/20/2006	EP1732580A2 Epha2 vaccines
12/20/2006	EP1732575A1 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
12/20/2006	EP1732574A1 The use of o-atp for the treatment of diseases involving angiogenesis
12/20/2006	EP1732573A1 Biologically active compounds with anti-angiogenic properties
12/20/2006	EP1732572A1 Control of feeding behavior by changing neuronal energy balance
12/20/2006	EP1732571A2 Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
12/20/2006	EP1732570A2 Novel hiv protease inhibitors
12/20/2006	EP1732569A1 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
12/20/2006	EP1732568A1 USES OF ERbeta MODULATORS
12/20/2006	EP1732567A1 Use of a phenothiazine derivative for preventing and/or treating hearing loss
12/20/2006	EP1732566A2 6-azaindole compound
12/20/2006	EP1732565A1 Sustained-release oral molsidomine composition for treating atherosclerosis
12/20/2006	EP1732564A1 Biaryl substituted pyrazinones as sodium channel blockers
12/20/2006	EP1732563A1 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
12/20/2006	EP1732562A2 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
12/20/2006	EP1732561A1 Combination of cb2 modulators and pde4 inhibitors for use in medicine
12/20/2006	EP1732560A1 Substituted cinnolin-4-ylamines
12/20/2006	EP1732559A2 Methods of treatment using eszopiclone
12/20/2006	EP1732558A1 1-[2h-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of pain
12/20/2006	EP1732557A1 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
12/20/2006	EP1732556A1 Process for the preparation of 3-amino-8-(1-piperazinyl)-2h-1-benzopyran-2-one and salts and hydrates thereof
12/20/2006	EP1732555A1 Opioid delivery system
12/20/2006	EP1732554A2 Treatment regimen for camptothecin derivatives
12/20/2006	EP1732553A1 Compounds for treating proliferative processes
12/20/2006	EP1732552A2 2,6-disubstituted piperidines as modulators of chemokine receptor activity
12/20/2006	EP1732551A1 Perhexilin for treating chronic heart failure
12/20/2006	EP1732550A2 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
12/20/2006	EP1732549A2 Methods for the treatment of synucleinopathies
12/20/2006	EP1732548A2 Methods of using sustained release aminopyridine compositions
12/20/2006	EP1732547A2 Anti-hiv quinuclidine compounds
12/20/2006	EP1732546A2 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
12/20/2006	EP1732545A1 Tetrahydro-beta-carboline compounds and use thereof
12/20/2006	EP1732544A2 Treatment of tremor with histamine h3 inverse agonists or histamine h3 antagonists
12/20/2006	EP1732543A2 Tetra-cyclic carboline deratives for inhibiting angiogenesis
12/20/2006	EP1732542A2 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder
12/20/2006	EP1732541A2 Cyclic compounds
12/20/2006	EP1732540A1 Oral health care drink and method for reducing malodors
12/20/2006	EP1732539A2 Use of beta-lapachone for the treatment of colon cancer
12/20/2006	EP1732538A1 Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia
12/20/2006	EP1732537A1 Benzofuranyl derivatives useful for the treatment of cardiac arrhythmia
12/20/2006	EP1732536A2 Triptolide lactone ring derivatives as immunomodulators and anticancer agents
12/20/2006	EP1732535A1 Injectable composition for the treatment of cancers
12/20/2006	EP1732534A1 Use of methylene amide derivatives in cardiovascular disorders
12/20/2006	EP1732533A1 Thyroid receptor agonists
12/20/2006	EP1732532A1 Novel pharmaceutical compositions comprising agonists of the thyroid receptor
12/20/2006	EP1732531A2 Amines and amides for the treatment of diseases
12/20/2006	EP1732530A1 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
12/20/2006	EP1732529A1 Gossypol co-crystals and the use thereof
12/20/2006	EP1732528A1 Bazedoxifene acetate solid dispersion formulations
12/20/2006	EP1732527A2 Use and administration of bacterial efflux pump inhibitors
12/20/2006	EP1732526A2 Salmeterol inhalation formulations
12/20/2006	EP1732525A1 Amorolfine patch for treating onychomycosis
12/20/2006	EP1732524A2 Methods and compositions for treatment of ion imbalances
12/20/2006	EP1732523A1 Ion binding polymers and uses thereof
12/20/2006	EP1732521A2 Compression-coated tablets and manufacture thereof
12/20/2006	EP1732520A1 Drug delivery system based on polyethylene vinylacetate copolymers
12/20/2006	EP1732519A1 Oral matrix formulations comprising licarbazepine
12/20/2006	EP1732518A1 Clarithromycin extended release formulation
12/20/2006	EP1732517A1 Prolonged-release compositions comprising torasemide and a matrix-forming polymer
12/20/2006	EP1732516A1 Ion binding compositions
12/20/2006	EP1732514A1 Crystalline composition containing escitalopram oxalate
12/20/2006	EP1732513A2 Rosiglitazone formulations
12/20/2006	EP1732512A2 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
12/20/2006	EP1732511A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose

1 ... 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 ... 7860